S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
Log in

IDEXX Laboratories Stock Price, Forecast & Analysis (NASDAQ:IDXX)

$259.70
+2.34 (+0.91 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
$256.96
Now: $259.70
$261.11
50-Day Range
$254.74
MA: $272.02
$286.17
52-Week Range
$176.11
Now: $259.70
$294.57
Volume43,668 shs
Average Volume480,935 shs
Market Capitalization$22.28 billion
P/E Ratio60.96
Dividend YieldN/A
Beta0.79
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.21 billion
Cash Flow$5.38 per share
Book Value$2.36 per share

Profitability

Net Income$377.03 million

Miscellaneous

Employees8,377
Market Cap$22.28 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.


IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Thursday, October, 31st. The company reported $1.24 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.14 by $0.10. The business had revenue of $605.30 million for the quarter, compared to analysts' expectations of $597.09 million. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. The firm's revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.05 earnings per share. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY20 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

What price target have analysts set for IDXX?

6 Wall Street analysts have issued twelve-month price objectives for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they anticipate IDEXX Laboratories' stock price to reach $293.33 in the next year. This suggests a possible upside of 13.0% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:
  • 1. According to Zacks Investment Research, "IDEXX exited the third quarter on an impressive note with better-than-expected numbers. The company’s solid organic revenue growth is encouraging. The top line was driven by strong sales at the CAG and LPD businesses. Specifically, the company witnessed sturdy gains from CAG Diagnostics in the quarter. It also witnessed strong performances in IDEXX VetLab consumables, reference laboratory diagnostic and consulting, and moderately robust growth in rapid assay products’ revenues globally. The global adoption of its latest products and services, including the rapid expansion of Catalyst installed base, and increased utilization of the Fecal Dx Antigen Panel and IDEXX SDMA test, is another driving factor. In the past one year, the stock outperformed its industry. However, a lowered EPS view for 2019 is a concern." (11/11/2019)
  • 2. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019)

Has IDEXX Laboratories been receiving favorable news coverage?

Press coverage about IDXX stock has been trending somewhat negative on Friday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IDEXX Laboratories earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for IDEXX Laboratories.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,220,000 shares, an increase of 7.0% from the September 30th total of 1,140,000 shares. Based on an average daily trading volume, of 401,800 shares, the days-to-cover ratio is currently 3.0 days. Approximately 1.5% of the company's stock are short sold. View IDEXX Laboratories' Current Options Chain.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), Paypal (PYPL), Adobe (ADBE), Micron Technology (MU), Alibaba Group (BABA), Mastercard (MA), Intuitive Surgical (ISRG), Intel (INTC) and Align Technology (ALGN).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (0.42%), Eagle Asset Management Inc. (0.40%), CIBC Private Wealth Group LLC (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), Carillon Tower Advisers Inc. (0.36%) and Stephens Investment Management Group LLC (0.31%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Chicago Capital LLC, Kornitzer Capital Management Inc. KS, Howland Capital Management LLC, Conestoga Capital Advisors LLC, Ardevora Asset Management LLP, Waratah Capital Advisors Ltd. and Creative Planning. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, First Trust Advisors LP, State of New Jersey Common Pension Fund D, Scout Investments Inc., Jag Capital Management LLC, Envestnet Asset Management Inc., California Public Employees Retirement System and Carillon Tower Advisers Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $259.70.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $22.28 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is http://www.idexx.com/.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  443 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  743
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel